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ABSTRACT
Background: Fibroblast growth factor-23 (FGF23) regulates body
phosphate homeostasis primarily by increasing phosphaturia. It also
acts as a vitamin D-regulating hormone. Maternal iron deficiency is
associated with perturbed expression and/or regulation of FGF23 and
hence might be implicated in the pathogenesis of hypophosphatemia-
driven rickets in their offspring.
Objectives: We aimed to determine the effect of antenatal oral iron
supplementation on FGF23 concentration and maternal and infant
markers of bone-mineral regulation.
Methods: We performed a secondary analysis of a trial in which
470 rural Kenyan women with singleton pregnancies and hemoglobin
concentrations ≥ 90 g/L were randomly allocated to daily, supervised
supplementation with 60 mg elemental iron as ferrous fumarate
or placebo from 13–23 weeks of gestation until 1 mo postpartum.
As previously reported, iron supplementation improved iron status
in mothers and neonates. For the present study, we reanalyzed all
available plasma samples collected in mothers and neonates at birth,
with primary outcomes being concentrations of FGF23, measured
by 2 assays: 1 that detects intact hormone and C-terminal cleavage
products (total-FGF23) and another that detects the intact hormone
only (intact-FGF23).
Results: Analysis was performed on 433 women (n = 216, iron
group; n = 217, placebo group) and 414 neonates (n = 207, iron
group; n = 207, placebo group). Antenatal iron supplementation
reduced geometric mean total-FGF23 concentrations in mothers and
neonates by 62.6% (95% CI: 53.0%, 70.3%) and 15.2% (95% CI:
−0.3%, 28.4%, P = 0.06), respectively. In addition, it increased
geometric mean neonatal intact-FGF23 concentrations by 21.6%
(95% CI: 1.2%, 46.1%), increased geometric mean maternal
hepcidin concentrations by 136.4% (95% CI: 86.1%, 200.3%), and
decreased mean maternal 25-hydroxyvitamin D concentrations by
6.1 nmol/L (95% CI: −11.0, −1.2 nmol/L).
Conclusions: Analysis of this randomized trial confirms that iron
supplementation can reverse elevated FGF23 production caused
by iron deficiency in iron-deficient mothers and their neonates.
Further investigations are warranted to assess to what extent iron
supplementation can prevent FGF23-mediated hypophosphatemic
rickets or osteomalacia. Am J Clin Nutr 2021;00:1–11.
Keywords: iron deficiency anemia, fibroblast growth factor
(FGF23), phosphate, vitamin D, bone, Africa, pregnancy
Introduction
There is increasing evidence that iron deficiency in children
with chronically inadequate calcium intake may predispose to
rickets, one of the most common noncommunicable childhood
diseases in developing countries (1). In this pathogenic pathway
(Figure 1), there seems to be a central role for fibroblast growth
factor-23 (FGF23), a key regulator of circulating concentrations
of phosphate and 1,25-dihydroxyvitamin D [1,25(OH)2D—
the bioactive form of vitamin D] (2). In vitamin D-replete
Gambian children, rickets was associated with elevated plasma
concentrations of total-FGF23 (as measured by an assay which
detects both the intact hormone and the C-terminal fragments
that result from its cleavage), 1,25(OH)2D, and total alkaline
phosphatase (a marker of dysregulated bone formation that is
elevated in rickets and osteomalacia) and with lower plasma
Am J Clin Nutr 2021;00:1–11. Printed in USA. © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
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concentrations of phosphate (3). Gambian children with a history
of rickets-like bone deformities had a higher prevalence of
anemia than community controls, and total-FGF23 concentration
was negatively associated with hemoglobin concentration (4).
In an iron supplementation study among Gambian children,
plasma total-FGF23 concentration at baseline was inversely
associated with markers of iron (plasma ferritin concentration,
hemoglobin concentration), whereas at 3 mo after the start of
iron supplementation, plasma total-FGF23 concentrations were
lower than at the start of the intervention (5). As with most
such studies, ethics constraints precluded the use of a placebo
control group. In a prospective cohort study, Gambian children
born to mothers who were iron deficient during pregnancy
had higher concentrations of total-FGF23 and total alkaline
phosphatase than those whose mothers had normal iron status
and this difference persisted ≤2 y of age (6). In mice, diet-
induced iron deficiency during pregnancy and nursing resulted
in elevated serum concentrations of total-FGF23 and intact-
FGF23 (as measured using an assay which only detects the intact
hormone), hypophosphatemia, and reduced serum concentrations
of 1,25(OH)2D in their pups (7). These data suggest that
maternal iron deficiency may lead to perturbations in FGF23
regulation that may in turn lead to hypophosphatemia-driven
rickets in the offspring. In addition, maternal bone mineral
density decreases by 3%–5% during pregnancy and lactation
(8). This physiological change, coupled with iron-deficiency
phosphate loss, may put additional pressures on the maternal
skeleton, thus predisposing iron-deficient women to poor bone
health in later life.
FGF23 gene expression occurs predominantly within osteo-
cytes but the FGF23 hormone regulates circulating phosphate
concentrations via the FGF receptor in renal tubule cells where
FGF23 signaling causes a reduction in phosphate resorption from
the glomerular filtrate and thus renal phosphate excretion. The
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intact FGF23 hormone undergoes proteolytic cleavage into its C-
and N-terminal fragments. Although the intact FGF23 hormone
is known to have effects on phosphate and vitamin D metabolism,
there is conflicting evidence as to whether the C-terminal FGF23
fragment is active, acts in the same way (9), or acts in the opposite
way to the intact hormone (10).
The requirement for iron and the demands on the kidney
increase during pregnancy, and the risk of developing iron
deficiency and/or anemia increases substantially. Iron absorption
and thus the effect of iron interventions on systemic biomarkers
(e.g., hemoglobin concentration) are known to depend on iron
status. This process is mediated by circulating concentrations
of hepcidin, the master regulator of body iron homeostasis.
Causality of the relations between iron deficiency and bone
metabolism has not yet been shown, because evidence has so
far been obtained exclusively from observational studies and
animal studies. Such an effect would be pertinent to developing
countries, where iron deficiency often affects the majority of
pregnant women and a substantial proportion of young children
(11).
The aim of this current study was to investigate the effect of
antenatal oral iron supplementation on circulating concentrations
of FGF23 and hence on markers of phosphate and bone
metabolism (including vitamin D) and kidney function at birth
in pregnant Kenyan women and their offspring. In addition,
we explored to what extent the response of these markers to
intervention depended on initial iron status.
Methods
Study design, participants, randomization, and blinding
The present study used samples and data that were collected
as part of a randomized placebo-controlled trial in rural Kenya
(NCT01308112) originally designed to measure the effect
of antenatal iron supplementation on maternal Plasmodium
infection risk, maternal iron status, and neonatal outcomes.
The recruitment for the original trial was conducted between
2011 and 2013. Study details and main results have been
published elsewhere (12). In brief, pregnant women aged 15–
45 y with singleton pregnancies, gestational age of 13–23 wk
(determined by obstetric ultrasonography), and hemoglobin
concentration ≥ 90 g/L were individually randomly assigned
at a 1:1 allocation ratio to 60 mg of elemental iron as ferrous
fumarate or placebo until 1 mo postpartum. The supplements
contained no other micronutrients and their neonates did not
receive any additional supplements. From screening until the
end of the intervention, local mill operators added fortificant
iron (target dose: 20 mg/kg flour) to grain routinely brought
for milling by homestead members of all the participating
women. Based on weighed intake studies, we estimate that
fortification supplied on average 5.7 mg of elemental iron as
ferric sodium ethylenediaminetetraacetate daily to the pregnant
women in both arms of the intervention. Participants and field
staff were blinded to the randomization and intervention until data
analysis.
All women provided written informed consent. Approval
for the original study was obtained from ethics committees at
the London School of Hygiene and Tropical Medicine, United
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FIGURE 1 Putative mechanisms whereby deficiencies of iron and calcium lead to hypophosphatemia and rickets. FGF23 is a hormone that is mainly
secreted by osteocytes in response to elevated concentrations of 1,25(OH)2D. FGF23 causes the internalization of sodium phosphate cotransporters in the
proximal tubule of the kidney, inhibiting 1-α-hydroxylase [which catalyzes the hydroxylation of 25(OH)D to 1,25(OH)2D] and stimulating expression of 24-
hydroxylase [which initiates the degradation of 1,25(OH)2D to an inactive form of vitamin D]. The net effect is an increased phosphate loss in the urine, an
accompanying reduction in circulating phosphate concentration, and a decrease in 1,25(OH)2D. Iron deficiency probably stimulates FGF23 gene expression
by activating HIF-1 (7, 13), the master transcriptional regulator of cellular and developmental responses to hypoxia. Iron deficiency also increases renal EPO
production. EPO mediates the relation between HIF-1 and FGF23 resulting in further increases in FGF23 gene expression (14). In osteocytes, a proportion of
FGF23 is normally broken down by proteolytic cleavage before secretion, resulting in both intact, biologically active hormone and C-terminal and N-terminal
fragments (with unclear biological activity) in the circulation (15). Some studies in healthy adults have indicated that low serum iron was associated with
elevated total-FGF23 but not intact-FGF23, suggesting that cleavage maintains phosphate homeostasis despite increased FGF23 expression (15, 16), whereas
others have shown that low serum iron is associated with elevated total- and intact-FGF23 (17, 18). EPO, erythropoietin; FGF23, fibroblast growth factor-23;
HIF-1, hypoxia inducible factor 1; intact-FGF23, intact fibroblast growth factor-23; total-FGF23, intact and C-terminal fragments of fibroblast growth factor-23;
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D.
Nairobi (ethics approval number KNH-ERC/A/453, 6/01/2010);
additional approval was obtained from the latter commit-
tee (KNH-ERC/A/272, P280/05/2017) to perform additional
analyses on archived plasma samples to generate the data
presented in this report.
Procedures
Maternal weight and height were measured at baseline, and
neonatal weight, length, and head circumference were measured
at birth. At baseline, we collected venous blood samples in
EDTA-coated tubes from women. We also collected maternal
venous blood, neonatal cord blood, and placental biopsies within
1 h postpartum. For home deliveries, samples were collected
within 2 h postpartum.
Plasma was stored within 2 h of blood collection in
liquid nitrogen (−196◦C) and subsequently frozen (−80◦C)
until analysis. We performed ELISA tests at the Medical
Research Council Elsie Widdowson Laboratory, Cambridge,
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collected at delivery: total-FGF23 using the C-terminal assay
(60-6100) which detects both the C-terminal fragment and the
intact hormone, and intact-FGF23 using the intact-FGF23 assay
(60-6600) which detects only the intact form of the hormone
(Immutopics); 1,25(OH)2D (the active metabolite of vitamin
D; Immunodiagnostic Systems); β-C-terminal telopeptide (β-
Crosslaps—a marker of bone resorption that is elevated in
increased bone resorption; Immunodiagnostic Systems); and
hepcidin (a regulator of iron metabolism that is low in iron
deficiency and raised by inflammation; Hepcidin-25, Bioac-
tive). Hemoglobin concentration was measured in the field by
photometer (HemoCue 301, Radiometer) and plasma α1-acid
glycoprotein (a marker of inflammation) and soluble transferrin
receptor (sTfR—a marker of iron status) were measured at
Meander Medical Centre, Amersfoort, Netherlands (UniCel DxC
880i analyzer, Beckman Coulter) as part of the original trial (12).
Plasma concentrations of ferritin, C-reactive protein (CRP—
a marker of inflammation), 25-hydroxyvitamin D [25(OH)D—
marker of vitamin D status], total alkaline phosphatase, intact
parathyroid hormone (PTH—a primary regulatory hormone of
calcium that is elevated in calcium deficiency), cystatin C
(a marker that is elevated in kidney dysfunction), and phos-
phate were measured at Meander Medical Centre, Amersfoort,
Netherlands (Architect c16000 and Architect i2000SR, Abbott).
ELISA assay accuracy was monitored across the working range
of assays using kit controls supplied by the manufacturers.
The UK laboratory was accredited by the Vitamin D External
Quality Assessment Scheme (http://www.deqas.org/) and the UK
National External Quality Assessment Service (https://ukneqas.
org.uk/) and the laboratory in the Netherlands by the External
Quality Assurance System (https://www.eurl-ar.eu/eqas.aspx)
and German Society for Clinical Chemistry and Laboratory
Medicine (DGKL) (https://www.dgkl.de/en/). In addition, an
aliquot of a pooled plasma sample was assayed in each batch
to monitor possible drift in measurements over time. Intra- and
interassay CVs were <7% and <6% for total-FGF23, intact-
FGF23, β-Crosslaps, 1,25(OH)2D, 25(OH)D, PTH, ferritin, CRP,
phosphate, total alkaline phosphatase, and cystatin C and <5%
and <17% for hepcidin, respectively.
Estimated glomerular filtration rate (eGFR—a measure of
kidney glomerular function) was calculated using equations
approved by the National Kidney Foundation (https://www.kidn
ey.org/professionals/KDOQI/gfr)—the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) cystatin C equations
for those aged >18 y: eGFR, mL·min−1·1.73 m−2 = 123.9
× [cystatin C (mg/L)/0.8]−1.328 × 0.996age and for those aged
≤18 y: eGFR, mL·min−1·1.73 m−2 = 70.69 × [cystatin C
(mg/L)]−0.931. At baseline, dipstick tests (Access Bio) were
used to detect histidine-rich protein-2 and lactate dehydrogenase
specific either to P. falciparum or to nonfalciparum human Plas-
modium species (12). qPCR was used to detect P. falciparum–
specific DNA in erythrocytes, and mothers were also tested
for HIV infection. HIV-infected mothers continued or were
offered antiretroviral treatment as part of their standard clinical
care.
Outcomes
The primary analysis concerned group differences in plasma
concentrations of total-FGF23 and intact-FGF23 in maternal
blood samples at delivery and neonatal cord blood samples.
As secondary outcomes, we studied other biomarkers of bone
metabolism and kidney function, namely, plasma concentrations
of phosphate, PTH, total alkaline phosphatase, β-Crosslaps,
25(OH)D, 1,25(OH)2D, cystatin C, and eGFR.
Statistical analysis
Sample size requirements were calculated based on the effect
of iron supplementation on Plasmodium infection risk (12) as
part of the original trial design; because they are not relevant to
the current study, they are not reported here. The current study
performed analysis on all available plasma samples from mothers
at birth (n = 433) and from infant cord blood (n = 414) at
delivery.
Anthropometric z scores for the neonates at birth were
derived with Kenyan children as a reference (19). The following
definitions were used: prematurity–being born at or before
37 completed weeks of gestation (<259 days of gestation as
calculated by early pregnancy ultrasound); anemia: hemoglobin
concentration < 110 g/L for pregnant women (19); iron defi-
ciency (depleted iron stores)–plasma ferritin concentration <15
μg/L for women and <12 μg/L for neonates (20); inflammation–
plasma CRP > 10 mg/L (21); vitamin D insufficiency–25(OH)D
concentration <50 nmol/L; and vitamin D deficiency–25(OH)D
concentration <30 nmol/L (22). There are no established
thresholds for intact-FGF23 or total-FGF23 concentrations or for
eGFR in pregnancy and neonates, or for anemia in neonates, and
so these variables were not dichotomized. Plasmodium infection
was defined as past or present maternal infection assessed at
parturition, regardless of species, as indicated by ≥1 positive test
results for the presence of Plasmodium lactate dehydrogenase
or P. falciparum–specific histidine-rich protein-2 in plasma or
by placental histopathology or P. falciparum DNA in maternal
erythrocytes from venous or placental blood by a PCR test.
Statistical analysis was performed using Stata version 16.0
(StataCorp). We visually inspected histograms to assess the shape
of the distribution and to identify possible outliers. Skewed data
were normalized by log transformation as appropriate. Groups
were described using mean ± SD for normally distributed data
and geometric mean ± geometric SD (GSD) for log-transformed
data. GSD was calculated as the exponentiated SD of the log-
transformed variable. It is a dimensionless factor that indicates
variation that is equivalent to subtraction or addition of 1 SD on a
log-transformed scale. For plasma CRP concentration at baseline,
we computed descriptive statistics with a Tobit model to account
for data being left-censored at the limit of quantification (1 mg/L).
Plasma concentrations of ferritin and soluble transferrin
receptor (sTfR) are affected by infection and inflammation
independently of iron status. We used multiple regression models
to adjust the iron markers for such effects (Supplemental
Methods). We used adjusted plasma iron markers to calculate
the body iron index, i.e., the ln of the ratio of the adjusted ferritin
concentration to the adjusted sTfR concentration. This indicator
has been shown to be linearly associated with quantitative
estimates of the size of the body iron store in iron-replete adults,
and with the size of the functional deficit that would need to be
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Crude intervention effects on continuous outcomes were
estimated by simple linear regression. To assess the potential
role of confounding due to imbalances in baseline variables,
we used multiple fractional polynomial regression to estimate
intervention effects adjusted for maternal characteristics as-
sessed at randomization, i.e., hemoglobin concentration, body
iron index, age, BMI, gestational age at delivery (calculated
from early pregnancy ultrasonography), parity, HIV infection,
and Plasmodium infection. Both in simple linear regression
models and in fractional polynomial models, we accounted for
heteroscedasticity of the error terms as appropriate (P values
for Breusch–Pagan/Cook–Weisberg tests < 0.05). Intervention
effects are reported as absolute differences in means for normally
distributed outcomes, or as relative differences in geometric
means for log-transformed outcomes.
For unadjusted prevalence differences, we used Newcombe’s
method to estimate 95% CIs and “N−1” chi-square tests
to compute P values (24). We used log-binomial regression
models (adjrr command in Stata package st0306.pkg) to estimate
prevalence differences adjusted for baseline characteristics, and
to estimate unadjusted prevalence differences when contingency
tables contained cells with expected values <10.
In a preplanned analysis, we used multiple fractional poly-
nomial regression analysis to explore to what extent iron
status at baseline modified the magnitude of the effect of
iron supplementation on FGF23 and selected markers of bone
metabolism at delivery, anticipating that iron absorption and
thus the response to administered iron would be larger in iron-
deficient women than in their iron-replete peers. We examined
such effect modification with a single independent variable (body
iron index) and 10 outcomes (see the Outcomes section), in both
mothers and neonates, which resulted in 20 analyses. We used the
mfpi procedure in Stata with the “flex(3)” specification to define
the flexibility of the main effects and interaction models with
adjustment for potentially influential maternal characteristics
assessed at randomization, i.e., hemoglobin concentration, BMI,
gestational age, parity, HIV infection, and Plasmodium infection.
We used a nominal significance level of 0.05 for selection of
variables and power functions; selection of linear, first-degree,
or second-degree polynomials was based on the lowest value for
Akaike’s information criterion. To check for possible overfitting
in the interaction models, we examined to what extent possible
trends in intervention effects observed across quintiles of body
iron index were consistent with effect modification as measured
by fractional polynomial regression.
Results
Primary outcome data were available for 433 women (92%
of 470 women randomly assigned to the intervention). Sample
sizes <433 reported in the subsequent sections were due to insuf-
ficient plasma volume being available for biochemical analysis
(Figure 2).
Maternal and neonatal biomarkers
At baseline, women had a mean age of 25.1 y, 16.2% were
nulliparous, 38.3% were anemic, 99.1% were iron deficient
(plasma ferritin concentration < 15 μg/L; values adjusted for
inflammation and Plasmodium infection), 34.4% had a current or
recent Plasmodium infection, and 21.7% were HIV-infected. At
baseline, anthropometric indexes, iron status, and infection status
were similar between intervention groups (Table 1).
Antenatal oral iron supplementation reduced the geometric
mean maternal concentration of total-FGF23 (by −62.6%) and
mean maternal concentration of 25(OH)D (by −6.1 nmol/L)
(Table 2). It also improved maternal iron status as shown by
an increased geometric mean concentration of hepcidin (by
136.4%); increased mean concentration of hemoglobin (by 9.0
g/L); increased geometric mean concentration of ferritin (by
95.6%); and a reduced prevalence of anemia (by 29.1%) and iron
deficiency (by 27.1%).
Antenatal oral iron supplementation reduced the geometric
mean neonatal total-FGF23 concentration (by 15.2%), whereas it
increased the geometric mean neonatal intact-FGF23 concentra-
tion (by 21.6%) (Table 2). It improved neonatal iron stores (mean
ferritin concentration increased by 23.3%) (Table 2) and other
neonatal outcomes (birth weight, length at birth, and gestational
duration increased by 141 g, 0.9 cm, and 3.4 d, respectively)
described in our previous publication (12).
No marked group differences were seen in the other maternal
or neonatal biomarkers of bone, kidney, or vitamin D metabolism.
As might be expected with a randomized trial of this size,
adjustment of treatment effects for baseline variables that were
considered a priori to be prognostic for outcome did not markedly
change effect estimates (Supplemental Table 1), showing that
effects are attributable to the intervention alone and not to
selection bias.
Influence of baseline variables on intervention effects
Figure 3 shows intervention × body iron index interactions for
selected outcomes. In women who received placebo (left panels,
red lines), low iron status at baseline (as indicated by body iron
index values) was associated with higher maternal concentrations
of total-FGF23, intact-FGF23, and cystatin C, as well as lower
neonatal intact-FGF23 concentration and lower maternal eGFR.
Consistent with these observations, we found that antenatal oral
iron supplementation reduced maternal total-FGF23 concentra-
tions (overall: by 62.6%) (Table 2), with the magnitude of this
effect being inversely associated with maternal iron status at
baseline (Figure 3, second right panel; P = 0.004). Similarly, we
found that antenatal oral iron supplementation increased neonatal
intact-FGF23 concentration, with the magnitude of the effect
being inversely associated with maternal iron status at baseline
(P = 0.04).
For maternal intact-FGF23 concentration, maternal cystatin
C concentration, and maternal eGFR, the effect of antenatal
iron supplementation also varied by initial maternal iron status
(Figure 3, right panels), but cumulative frequency distributions
(Figure 3, left panels, gray lines) indicated that most women
had body iron index values around the cutoffs that deter-
mined whether the effect of intervention was either positive
or negative (intact-FGF23, eGFR) or body iron index values
within the range of no effect (cystatin C). This may explain
the absence of marked effects in the unadjusted analysis
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FIGURE 2 Flow-through of participants in the study and blood samples available for analysis.
Analysis of effect modification by body iron index quan-
tiles showed similar patterns as aforementioned (Supple-
mental Figure 1), indicating that the results presented in
Figure 3 are not the result of overfitting. There was no
evidence for effect modification for the other outcomes
considered.
Discussion
To our knowledge, we report the first randomized placebo-
controlled trial to assess the effect of oral iron supplementation
on FGF23 concentrations in persons without kidney disease.
Antenatal iron supplementation reduced maternal total-FGF23
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TABLE 1 Maternal characteristics at baseline, by intervention group1
Characteristic Placebo (n = 217) Iron (n = 216)
Age, y 25.0 ± 6.1 25.1 ± 6.1
Parity,2 n 2 (0–10) 2 (0–9)
Nullipara 19.8 [43] 12.5 [27]
Height, cm 162.4 ± 6.8 162.5 ± 5.9
Weight, kg 57.4 ± 7.4 58.0 ± 7.5
Gestational age at randomization,3 wk 17.5 ± 1.2 17.9 ± 1.2
Hemoglobin concentration, g/L 112.4 ± 11.8 113.4 ± 10.7
Anemia (hemoglobin concentration < 110 g/L) 40.5 [88] 36.1 [78]
Plasma ferritin concentration,3 μg/L 15.9 ± 2.5 16.3 ± 2.4
Iron deficiency (plasma ferritin concentration < 15 μg/L)
Without adjustment for inflammation and infection4 53.5 [116] 53.7 [116]
With adjustment for inflammation and infection4 99.5 [216] 98.6 [213]
Plasma CRP concentration,3,5 mg/L 4.1 ± 3.72 4.0 ± 3.79
Plasma AGP concentration, g/L 0.78 ± 0.27 0.76 ± 0.26
Inflammation (plasma CRP ≥ 10 mg/L) 26.7 [58] 23.6 [51]
Current Plasmodium infection 36.4 [79] 32.4 [70]
HIV infection 21.7 [47] 21.8 [47]
1Values are mean ± SD or percentage [n] unless otherwise indicated. AGP, α1-acid glycoprotein; CRP,
C-reactive protein.
2Median (range).
3Geometric mean ± geometric SD.
4Adjustment based on plasma CRP concentration, plasma AGP concentration, and Plasmodium infection (see
Supplemental Methods).
5Based on log-transformed data and a Tobit model to account for left-censoring at the limit of quantification
(1 mg/L).
at delivery. The magnitude of the effect on maternal total-
FGF23 concentrations was inversely associated with initial
maternal iron status. Iron supplementation decreased total-
FGF23 concentration and increased intact-FGF23 concentration
in neonates, and there was evidence that the magnitude and the
direction of the intervention effect on neonatal intact-FGF23
concentration depended on initial maternal iron status. Although
there was no measurable overall effect of iron supplementation
on maternal intact-FGF23 concentration, maternal cystatin C
concentration, and maternal eGFR, we found that initial maternal
iron status may have influenced the direction and magnitude of
these effects. Lastly, iron supplementation decreased maternal
25(OH)D concentration, but there was no evidence that this effect
depended on initial maternal iron status (12).
The strengths of this study include its randomized design;
large sample size; supervised administration of supplements with
excellent adherence (iron: 100%; placebo: 99.1%) (12); blinding
of participants, field staff, and laboratory staff to the intervention;
the use of a placebo as a comparator; and the inclusion of iron-
deficient and anemic women in the trial. One study limitation
is that we assessed intervention effects on multiple endpoints,
which has the inherent risk of multiplicity. On the other
hand, effects on related outcomes can be mutually reinforcing
instead of undermining (25). This point is underscored by our
finding that iron supplementation led to increased maternal
ferritin concentrations (Table 2), which lends credence to the
concurrent increase in maternal hemoglobin concentrations: both
findings indicate that the intervention improved maternal iron
status. Results of the intervention × baseline body iron index
interactions should be interpreted with caution and considered as
exploratory because of the potential instability of the functions
found, and because further studies are needed to validate the
body iron index, adjusted for inflammation and infection, as
an indicator of body iron status. In addition, in light of the
decreases in 25(OH)D concentrations and the known effects of
iron supplements on intestinal calcium absorption, it is likely that
iron supplementation affects calcium metabolism. This finding
could not be further investigated because blood samples were
collected in EDTA-coated tubes which inhibits accurate calcium
measurement. Plasma erythropoietin (EPO) concentration was
not measured owing to constraints in available plasma volume
and so could not be investigated in the causal pathway between
iron supplementation and total-FGF23 reduction. An additional
limitation is that certain characteristics that may have affected the
outcome were not measured at baseline. However, with sample
sizes >200/group, simple randomization normally yields only
mild disparities in sample sizes between groups (26). Thus,
it is unlikely that group imbalances in prognostic variables at
baseline led to substantial selection bias in our effect estimates.
The marked reduction in maternal and neonatal total-FGF23
concentrations after antenatal iron supplementation is in keeping
with previous studies (6, 7) and is likely caused by a reversal
of hypoxia and/or EPO-driven FGF23 gene expression in
osteocytes that occurs in iron deficiency (7). Consistent with
this hypothesis, we found that the reduction in total-FGF23
was most pronounced in mothers with the lowest body iron
status.
Our findings corroborate emerging evidence that orally
administered iron does not normally lead to measurable changes
in maternal plasma concentrations of intact-FGF23 or phosphate
(6). Iron deficiency results in increased concentrations of
hypoxia-inducible factor 1α, which stimulates FGF23 transcrip-
tion through increased EPO production and perhaps also by
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TABLE 2 Effect of antenatal iron supplementation on maternal and neonatal biomarkers at birth1
Maternal blood Neonatal (cord) blood
Biomarker concentration or status n Mean ± SD Effect (95% CI) P value n Mean ± SD Effect (95% CI) P value
Total-FGF23,2 RU/mL
Placebo 217 370.3 ± 3.62 Reference 207 647.3 ± 2.29 Reference
Iron 216 138.4 ± 3.09 − 62.6% (−70.3%, −53.0%) <0.0005 207 548.6 ± 2.50 − 15.2% (−28.4%, 0.3%) 0.06
Intact-FGF23,2 ng/L
Placebo 217 41.3 ± 1.54 Reference 205 6.1 ± 2.65 Reference
Iron 216 39.4 ± 1.46 − 4.5% (−11.5%, 3.1%) 0.24 200 7.4 ± 2.47 21.6% (1.2%, 46.1%) 0.04
25-hydroxyvitamin D, nmol/L
Placebo 217 99.6 ± 28.7 Reference 204 63.1 ± 19.3 Reference
Iron 216 93.5 ± 23.0 − 6.1 (−11.0, −1.2) 0.01 206 61.5 ± 17.7 − 1.6 (−5.2, 2.0) 0.37
Inadequate 25-hydroxyvitamin D (<50 nmol/L)
Placebo 217 2.8 [6] Reference 204 23.5 [48] Reference
Iron 216 3.7 [8] 0.9% (−3.0%, 5.0%) 0.96 206 25.2 [52] − 1.7% (−10.0%, 6.6%) 0.97
1,25-dihydroxyvitamin D, pmol/L
Placebo 203 351.0 ± 78.2 Reference 195 203.0 ± 62.9 Reference
Iron 200 351.1 ± 84.4 0.1 (−15.8, 16.0) 0.98 195 203.9 ± 52.7 0.8 (−10.6, 12.4) 0.88
Parathyroid hormone,2 pmol/L
Placebo 217 4.0 ± 1.94 Reference 205 0.5 ± 2.69 Reference
Iron 216 3.9 ± 1.92 − 2.0% (−13.4%, 10.9%) 0.75 206 0.5 ± 2.97 − 3.3% (−21.0%, 18.3%) 0.74
Phosphate, mmol/L
Placebo 217 1.27 ± 0.32 Reference 205 2.05 ± 0.64 Reference
Iron 216 1.29 ± 0.24 0.03 (−0.03, 0.08) 0.30 206 2.11 ± 0.65 0.06 (−0.07, 0.18) 0.38
Total alkaline phosphatase,2 U/L
Placebo 217 102.3 ± 1.88 Reference 205 17.3 ± 1.74 Reference
Iron 215 96.1 ± 1.86 − 6.0% (−16.5%, 5.7%) 0.30 206 17.6 ± 2.22 2.6% (−10.2%, 10.2%) 0.77
β-Crosslaps,2 μg/L
Placebo 210 0.6 ± 1.81 Reference 206 0.8 ± 1.22 Reference
Iron 209 0.7 ± 1.70 7.2% (−3.7%, 19.4%) 0.20 206 0.8 ± 1.27 1.5% (−2.7%, 5.9%) 0.48
Cystatin C, mg/L
Placebo 217 1.26 ± 0.29 Reference 205 2.06 ± 0.40 Reference
Iron 216 1.25 ± 0.30 0.00 (−0.06, 0.05) 0.90 206 2.06 ± 0.37 0.00 (−0.07, 0.08) 0.97
eGFR,2 mL · min−1 · 1.73 m−2
Placebo 217 62.1 ± 1.32 Reference 205 36.6 ± 1.18 Reference
Iron 216 62.4 ± 1.32 0.5% (−4.6%, 5.8%) 0.86 206 36.6 ± 1.19 0.0% (−3.3%, 3.4%) 1.00
Hepcidin,2 μg/L
Placebo 217 1.9 ± 3.41 Reference 207 8.1 ± 2.30 Reference
Iron 216 4.4 ± 3.69 136.4% (86.1%, 200.3%) <0.0005 207 9.1 ± 2.24 12.2% (−4.3%, 31.4%) 0.16
Hemoglobin, g/L
Placebo 214 111.6 ± 19.0 Reference 209 150.6 ± 21.0 Reference
Iron 215 120.7 ± 16.4 9.0 (5.7, 12.4) <0.0005 206 153.8 ± 21.7 3.2 (−1.0, 7.3) 0.13
Anemia (hemoglobin < 110 g/L for mothers)
Placebo 214 50.5 [108] Reference —
Iron 215 21.4 [46] − 29.1% (−37.4%, −20.1%) <0.001 —3
Ferritin,2 μg/L
Placebo 217 19.0 ± 2.61 Reference 205 103.0 ± 2.11 Reference
Iron 216 37.1 ± 2.55 95.6% (63.6%, 133.9%) <0.0005 206 127.0 ± 2.14 23.3% (6.6%, 42.7%) 0.005
Iron deficiency (ferritin ≤ 15 μg/L mothers and <12 μg/L for neonates)
Placebo 217 43.3 [94] Reference 205 0.9 [2] Reference
Iron 216 16.2 [35] − 27.1% (−35.0%, −18.7%) <0.001 205 0.0 [0] —4 ND
CRP, mg/L
Placebo 217 6.7 ± 3.93 Reference 131 0.2 [0.2–0.3] Reference
Iron 216 7.7 ± 3.69 16.4% (−9.6%, 49.8%) 0.24 128 0.2 [0.2–0.3] —5 0.62
Inflammation (CRP > 10 mg/L)
Placebo 217 38.2 [83] Reference 131 5.3 [7] Reference
Iron 216 39.8 [86] 1.6% (−7.6%, 10.7%) 0.74 128 1.6 [2] − 3.8% (−8.2%, 0.6%) 0.09
1Values are mean ± SD or % [n] unless indicated otherwise. Effects are reported as absolute difference in means, relative difference (%) in geometric means, or difference in prevalence,
with placebo as the reference group. Group estimates are medians [IQRs]; group differences in distributions were compared by independent-samples Mann–Whitney U test, which yields a P
value only. For continuous outcomes, P values were obtained by simple linear regression analysis, accounting for heteroscedasticity. For binary outcomes, we used Newcombe’s method to
estimate 95% CIs and “N−1” chi-square tests to compute P values. We used log-binomial regression models to estimate prevalence differences when contingency tables contained cells with
expected values <10. P values indicate the probability of data occurring as observed or being more extreme than observed under the assumption of no effect, i.e., outcomes being identically
distributed for groups that received supplementation with either placebo or iron. β-Crosslaps, β-C-terminal telopeptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate;
intact-FGF23, intact fibroblast growth factor-23; ND, not determined; total-FGF23, intact and C-terminal fragments of fibroblast growth factor-23.
2Geometric mean ± geometric SD.
3Effects on anemia were not calculated in neonates because anemia is poorly defined in this group.
4Not determined as there were too few cases of iron deficiency to allow analyses.
5Plasma CRP concentration in cord blood was highly skewed and could not be normalized by log transformation.
increase in FGF23 production does not normally result in
maternal hypophosphatemia; excess FGF23 is proteolytically
cleaved within osteocytes, resulting in increased secretion of C-
terminal FGF23 fragments into the circulation (which is reflected
in total-FGF23 concentrations), whereas concentrations of the
biologically active intact hormone remain largely unaffected
(27). By contrast, some intravenous iron preparations (e.g.,
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FIGURE 3 Effect of iron supplementation on selected outcomes at delivery, by iron status at baseline. Cumulative frequency distribution is represented
by the gray line. The dependent variables are all maternal outcomes (iron, n = 216; placebo, n = 217) except for neonatal intact-FGF23 concentration (iron,
n = 200; placebo, n = 205). Iron status is indicated by body iron index, i.e., the ln of the ratio of plasma concentrations of ferritin (μg/L) to plasma concentrations
of soluble transferrin receptor (mg/L), both adjusted for plasma concentrations of C-reactive protein, α1-acid glycoprotein, and Plasmodium infection. P
values were obtained by multiple fractional polynomial regression analysis, with adjustment for potentially influential maternal characteristics assessed at
randomization, i.e., hemoglobin concentration, BMI, gestational age, parity, HIV infection, and Plasmodium infection. Left panels: associations between
outcomes and body iron index for women who received supplementation with iron (blue lines) or placebo (red lines). The difference between these lines is the
treatment effect (i.e., the relative difference in outcome between the iron group and the placebo group, with the placebo group used as the reference) conditional
to body iron index. Right panels: treatment effect as a function of body iron index, with corresponding 95% confidence bands and P values. Horizontal dashed
lines indicate zero effect and the unadjusted effect as measured in a regression model without covariates other than the intervention (Table 2). eGFR, estimated
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block cleavage of FGF23, thus leading to FGF23-mediated
phosphaturia and a concomitant decrease in circulating phosphate
concentrations (15). Although hypophosphatemia due to single-
dose administration of intravenous iron is often transient and
asymptomatic, it can persist for >1 mo, and some patients
develop severe and symptomatic hypophosphatemia with serious
musculoskeletal complications, including osteomalacia, fragility
fractures, and hypoxemia (28).
In the present study, the effect of the iron intervention
on maternal intact-FGF23 concentration varied with baseline
iron status (Figure 3), suggesting that FGF23 transcription
and cleavage are uncoupled in women with poor iron status.
In our study, this occurred in ∼40% of women (the lowest
2 quintiles; see Supplemental Figure 1). Chronically elevated
concentrations of intact-FGF23 result in phosphaturia and
eventually hypophosphatemia, which in turn can lead to serious
musculoskeletal complications, including rickets in children
and osteomalacia fragility fractures in adults. However, overall
we found no evidence that iron affected plasma phosphate
concentrations or bone turnover, although the intervention period
(∼5 mo) may have been insufficient to detect changes in these
markers. Further studies are needed to discount the possibility
that moderate to severe iron deficiency causes hyperphosphaturia
and hypophosphatemia in pregnant women. Special caution is
warranted when prescribing intravenous ferric carboxymaltose to
individuals with iron deficiency.
Our findings suggest that iron supplementation leads to
increased glomerular filtration rates in women with poor iron
status. This discovery is in agreement with a Mendelian
randomization study that showed serum iron concentration to be
associated with glomerular filtration rates (29). In a randomized
controlled trial in Bangladesh, children whose mothers had
antenatally received a daily oral supplement containing 60 mg
Fe/d had higher glomerular filtration rates at 4.5 y of age than
those whose mothers received 30 mg Fe/d (30). Children with
a history of rickets had a reduced glomerular filtration rate as
estimated from plasma cystatin C concentration (4). Further work
is needed to elucidate a possible role of kidney function along the
causal pathway between iron and rickets.
In a prospective cohort study, increased total-FGF23 concen-
tration was associated with an increase in all-cause mortality
in a general population of older US adults (31). Although this
association may have been in part confounded by the effect
of inflammation on FGF23 expression, it is possible that the
reduction that is seen in maternal and infant total-FGF23 after
antenatal iron supplementation confers a general health benefit.
Intriguingly, and in contrast to effects observed in pregnant
women, antenatal iron supplementation led to increased intact-
FGF23 concentrations in neonates, which conversely suggests
that maternal iron deficiency during pregnancy leads to decreased
neonatal intact-FGF23 concentrations, without an apparent effect
on neonatal serum phosphate concentration. These findings
contradict reports from a study in neonatal pups born to female
wild-type mice which were fed an iron-deficient diet during
the third week of pregnancy (corresponding to the human third
trimester) and during lactation, and which developed increased
concentrations of both intact-FGF23 and total-FGF23, as well
as decreased phosphate concentrations (7). From that report (7),
however, it is not clear whether these outcomes were measured
immediately after birth.
In an earlier prospective cohort study, poor maternal iron status
during pregnancy was associated with a higher total-FGF23
concentration but similar intact-FGF23 concentrations in infants
and young children (6). Unfortunately, however, these markers
were not assessed at delivery. In contrast to the critical role that
FGF23 plays in regulating phosphorus and skeletal metabolism in
adults and children, murine studies suggest that FGF23 may not
be required to regulate fetal phosphorus homeostasis, placental
phosphorus transport, or skeletal development, perhaps because
the placenta’s role to actively transport phosphorus and other
minerals from the maternal circulation is independent of FGF23
(32). In mice, fetal phosphate concentrations are relatively high
and decrease within a few days after birth, concurrently with
the cessation of placental phosphate influx. Within hours to days
after loss of the placental phosphorus pump, neonatal FGF23
becomes an important regulator of renal phosphorus excretion
and intestinal phosphorus absorption (32). It is possible that the
effects of antenatal iron supplementation on offspring FGF23
and phosphate metabolism may only become apparent later in
infancy, and not at birth and so were not fully captured in this
study.
Antenatal iron supplementation also had an effect on vitamin
D metabolism by decreasing maternal 25(OH)D concentration.
Emerging evidence has found a biological link between vitamin
D and iron metabolism. The vitamin D response element has
been identified on HAMP (the gene encoding hepcidin), and
1,25(OH)2D has been shown to suppress hepcidin expression
and thereby increase the amount of iron absorbed from the
diet and released from stores (33). It is possible that there is a
negative feedback loop whereby when hepcidin concentrations
are high (in iron repletion, or with antenatal iron supplementation
or with inflammation), 25(OH)D concentration decreases. An
alternative pathway for decreases in maternal 25(OH)D is
through direct effects of FGF23 on vitamin D metabolism.
Higher FGF23 concentrations are known to downregulate
Cytochrome P450 Family 27 Subfamily B Member 1 (CYP27B1)
expression and upregulate Cytochrome P450 Family 24 Sub-
family A Member 1 (CYP24A1) expression with the potential
to lower 1,25(OH)2D and raise 24,25(OH)2D, respectively
(34).
We conclude that antenatal oral iron supplementation can
redress perturbances in maternal and neonatal FGF23 metabolism
induced by maternal iron deficiency during pregnancy. This
suggests the possibility that iron supplementation could help
prevent rickets and osteomalacia in individuals with an impaired
ability to regulate FGF23 concentration.
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